Nine More FDA Bulk Compounding Denials Proposed Post-Vasopressin
Executive Summary
Expected flurry of FDA proposals against 503B compounding from bulk drug substances follows vasopressin court ruling.
You may also be interested in...
US FDA 'Bulks Up' 503B Outsourcing Drug List By Proposing Four First-Time Additions
The US FDA has proposed allowing outsourcing facilities to compound from four drug substances, but not from 19 others that it says already are available in FDA-approved drug products. Compounding pharmacies also would be allowed to compound from two of the four drug substances.
The FDA Proposes Adding Five Of 31 Drug Substances To 503A Bulks List
FDA proposal would allow traditional compounding from five drug substances based on medical need, but not from another 26.
Vasopressin Ruling May Greenlight More FDA Limits On Bulk Drug Compounding
By siding with the FDA against bulk compounding of vasopressin, is court encouraging more limits to Section 503B outsourcing facilities?